Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Next Previous
X
Search
Trial Profile

A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Batoprotafib (Primary) ; Opnurasib (Primary) ; Tislelizumab (Primary)
  • Indications Biliary cancer; Carcinoma; Colorectal cancer; Duodenal cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms KontRASt-01
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals

    • Most Recent Events

    • 12 Sep 2023 Results (n=50), assessing preliminary safety and efficacy of JDQ443 + TNO155 in patients with advanced, KRAS G12C-mutated solid tumors, presented at the 24th World Conference on Lung Cancer.
    • 06 Jun 2023 Results assessing safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer presented at the 59th Annual Meeting of the American Society of Clinical Oncology
    • 18 May 2023 Planned number of patients changed from 425 to 475.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top